EMAIL DETAILS

Please keep this between us

Sent from my iPhone

Begin forwarded message:

> From: Derrick Johns <derrick@difusiontech.com>
> Date: March 24, 2015 at 6:09:38 PM EDT
> To: david keoghan <davidkeoghan@me.com>, Brian Parker <brian@pharmaguard.ie>, Dan George <dancg60@hotmail.com>, Andrew Bazos <abazos@gmail.com>, Joseph Crudden <srodain@aol.com>
> Cc: "ng.evan@dorsey.com" <ng.evan@dorsey.com>
> Subject: FW: Structure Suggestion
>
> All,
>
> We are talking about Aram closing out the B round for $2.2mm this Friday with a first right of refusal on next round. Stay tuned. Looking to close in DC on April 23rd.
>
> Derrick W. Johns
> CEO and Founder
>
> www.difusiontech.com
>
> "All Truths are easy to understand once discovered,
> the point is to discover them” - Galileo
>
> (512) 863-7777 o
> (512) 284-3338 c
>
>
>
> From: Lewis Tepper <ltepper@astonpartners.com>
> Date: Tuesday, March 24, 2015 at 3:53 PM
> To: Derrick Johns <derrick@difusiontech.com>
> Subject: Re: Structure Suggestion
>
> ​Hey Derrick:
>
>
>
> Can we set up to talk briefly on Friday?
>
>
>
> Also, do you know the per share price you did the series A round at?
>
>
>
> Thanks
>
> From: Derrick Johns <derrick@difusiontech.com>
> Sent: Monday, March 23, 2015 4:33 PM
> To: Lewis Tepper
> Subject: Structure Suggestion
>
> Lewis,
>
> If your group still has interest in moving forward and I am assuming they are. The Irish are going to propose Key Capital finishing what is left of the B Series ($2.2mm) then acting as a broker for a PE deal next year.
>
> That structure is a departure from the "sell it early or grow it big” inflection point the company is currently considering. However, in keeping with the grow it big strategy we would embark upon together. We may want to consider a similar milestone structure; with the first tranche being the completion of the B round. Under that scenario you would control 2 of 5 board seats on completion of b round We can figure out additional seats valuation and milestones for follow on funding.
>
> Those funds would be all used for new management, infrastructure to support sales and additional R&D 12 –14 months. We can predicate the follow on funding on US Commericlalization/FDA clearance.
>
> Just me thinking out load to keep pace with the Irish…open to any input.
>
> Derrick W. Johns
> CEO and Founder
>
> www.difusiontech.com
>
> "All Truths are easy to understand once discovered,
> the point is to discover them” - Galileo
>
> (512) 863-7777 o
> (512) 284-3338 c
>
>
>
>=2